Asset
Lunsotogene Parvec
Regeneron Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05788536 | phase1_2 | recruiting | 2023-06-27 | 2029-02-26 | Regeneron Pharmaceuticals | A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 125874 | BLA | Regeneron Pharmaceuticals, Inc. |
Marketed products (1)
- OTARMENI